Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Dompé Farmaceutici S.p.A clinical trials
The registry lists 52 studies whose lead sponsor is Dompé Farmaceutici S.p.A. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Dompé Farmaceutici S.p.A studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Dompé Farmaceutici S.p.A.
- Dompé Farmaceutici S.p.A52 studiesSame company
Something wrong?
Focus areas
Conditions Dompé Farmaceutici S.p.A leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 52. Browse all 52 →
- An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye DiseaseRecruitingNCT07503886Phase 2
- An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDRecruitingNCT07519902Phase 3
- An Efficacy and Safety Study of DFL24498 in the Treatment of AKCRecruitingNCT07395232Phase 3
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)RecruitingNCT07453888Phase 3
- A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell FunctionTerminatedNCT04628481Phase 2
- Add-on Reparixin in Adult Patients With ARDSCompletedNCT05496868Phase 2
- Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired PneumoniaTerminatedNCT05254990Phase 3
- A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.CompletedNCT06244316Phase 2
- DEFENDO Long Term Follow-up Study in Stage 1 NK PatientsCompletedNCT05552261
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye DiseaseCompletedNCT05136170Phase 3
- Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry EyeTerminatedNCT06411132
- Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic KeratitisCompletedNCT04485546Phase 4
- A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.TerminatedNCT04899271Phase 2
- Tolerability, Safety and Efficacy of Lubricin vs Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry EyeCompletedNCT02510235Not applicable
- Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.TerminatedNCT05368402Phase 2
- Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver TransplantationTerminatedNCT03031470Phase 2
- A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy MalesCompletedNCT04802967Phase 1
- Repertaxin in Prevention of Primary Graft Dysfunction After Lung TransplantationCompletedNCT00224406Phase 2
- Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.CompletedNCT03031327Not applicable
- Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic KeratitisWithdrawnNCT06411145Phase 4
- Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL SyrupCompletedNCT02858193Phase 1
- Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry EyeCompletedNCT02507934Not applicable
- Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.CompletedNCT04878055Phase 3
- Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)CompletedNCT05133180Phase 3
- To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast CancerWithdrawnNCT05212701Phase 2
- Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755ATerminatedNCT04803396Phase 1
- A Study to Assess Efficacy and Tolerability of Ketoprofen 40 mg Granules vs PlaceboCompletedNCT03836807Phase 3
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy VolunteersCompletedNCT01744704Phase 1
- Crossover, Single Dose Randomized, Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Oral SolutionCompletedNCT02350296Phase 1
- A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry EyeCompletedNCT03982368Phase 2
- Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry EyeCompletedNCT02101281Phase 2
- A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 DiabetesCompletedNCT02814838Phase 2
- A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive SurgeryCompletedNCT03035864Phase 2
- Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.CompletedNCT01756456Phase 1/2
- A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)CompletedNCT02110225Phase 1/2
- Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry CoughCompletedNCT03837938Phase 3
- A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy VolunteersCompletedNCT04854642Phase 1
- Reparixin in Prevention of Delayed Graft Function After Kidney TransplantationCompletedNCT00248040Phase 2
- Reparixin in COVID-19 Pneumonia - Efficacy and SafetyTerminatedNCT04794803Phase 2/3
- Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet TransplantationCompletedNCT01817959Phase 3
- Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.CompletedNCT05172050Phase 2/3
- Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy VolunteersCompletedNCT03836859Phase 1
- Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 DiabetesWithdrawnNCT05035368Phase 2
- Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous PemphigoidTerminatedNCT01571895Phase 2
- Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantationCompletedNCT01967888Phase 2/3
- Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NKCompletedNCT02227147Phase 2
- A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerCompletedNCT02370238Phase 2
- Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)CompletedNCT02001974Phase 1
- Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast CancerTerminatedNCT01861054Phase 2
- Reparixin in Pancreatic Islet TransplantationCompletedNCT01220856Phase 2